[go: up one dir, main page]

MX2015018040A - Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico. - Google Patents

Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico.

Info

Publication number
MX2015018040A
MX2015018040A MX2015018040A MX2015018040A MX2015018040A MX 2015018040 A MX2015018040 A MX 2015018040A MX 2015018040 A MX2015018040 A MX 2015018040A MX 2015018040 A MX2015018040 A MX 2015018040A MX 2015018040 A MX2015018040 A MX 2015018040A
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
movement disorders
hyperkinetic movement
therapeutic agents
Prior art date
Application number
MX2015018040A
Other languages
English (en)
Other versions
MX366353B (es
Inventor
GAVALDÁ BATALLA Núria
Insa Boronat Raúl
Reig Bolaño Núria
Original Assignee
Som Innovation Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015018040(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech S L filed Critical Som Innovation Biotech S L
Publication of MX2015018040A publication Critical patent/MX2015018040A/es
Publication of MX366353B publication Critical patent/MX366353B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de (RS)-[2-(3,4-dimetoxife nil)etil] [2-hidroxi-3-(3-metilfenoxi) propil]amina que tienen la fórmula (IA) o una sal farmacéuticamente aceptable del mismo para la formulación de una composición farmacéutica, útil para la profilaxis y/o el tratamiento de trastornos de movimiento hipercinéticos asociados con enfermedad de Huntington, enfermedad de Wilson, síndrome de Touret, síndrome de piernas inquietas, y disquinesia tardía.
MX2015018040A 2013-06-19 2014-06-18 Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico. MX366353B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382230 2013-06-19
PCT/EP2014/062786 WO2014202646A1 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
MX2015018040A true MX2015018040A (es) 2016-08-03
MX366353B MX366353B (es) 2019-07-05

Family

ID=48672545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015018040A MX366353B (es) 2013-06-19 2014-06-18 Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico.

Country Status (20)

Country Link
US (2) US9789072B2 (es)
EP (1) EP3010543B1 (es)
JP (1) JP6476174B2 (es)
KR (1) KR102254542B1 (es)
CN (1) CN105658238B (es)
AU (1) AU2014283319B2 (es)
BR (1) BR112015031835B1 (es)
CA (1) CA2915811C (es)
CL (1) CL2015003679A1 (es)
DK (1) DK3010543T3 (es)
ES (1) ES3053333T3 (es)
HK (1) HK1223014A1 (es)
IL (1) IL243192B (es)
MX (1) MX366353B (es)
PL (1) PL3010543T3 (es)
PT (1) PT3010543T (es)
RU (1) RU2685502C2 (es)
SG (1) SG11201510451RA (es)
WO (1) WO2014202646A1 (es)
ZA (1) ZA201600312B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41557A (fr) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
CN111372567B (zh) * 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
CN111836543A (zh) 2017-10-10 2020-10-27 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790165A (fr) * 1971-12-14 1973-02-15 Parke Davis & Co Nouveaux aminoalcanols et procede pour les preparer
EP2170805B1 (en) 2007-06-21 2016-03-16 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US8197858B2 (en) 2009-02-06 2012-06-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments
SI2560631T1 (sl) 2011-03-01 2014-06-30 Pharnext Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань

Also Published As

Publication number Publication date
EP3010543A1 (en) 2016-04-27
IL243192B (en) 2019-12-31
DK3010543T3 (da) 2025-12-01
WO2014202646A1 (en) 2014-12-24
US20160158167A1 (en) 2016-06-09
PL3010543T3 (pl) 2026-01-19
CL2015003679A1 (es) 2016-09-02
IL243192A0 (en) 2016-02-29
EP3010543B1 (en) 2025-11-05
KR102254542B1 (ko) 2021-05-24
JP6476174B2 (ja) 2019-02-27
AU2014283319B2 (en) 2019-07-25
US20180042869A1 (en) 2018-02-15
HK1223014A1 (zh) 2017-07-21
BR112015031835A2 (pt) 2017-07-25
RU2685502C2 (ru) 2019-04-19
ZA201600312B (en) 2022-12-21
US9789072B2 (en) 2017-10-17
JP2016522235A (ja) 2016-07-28
BR112015031835A8 (pt) 2019-12-31
NZ715951A (en) 2021-03-26
CN105658238A (zh) 2016-06-08
KR20160055121A (ko) 2016-05-17
CA2915811A1 (en) 2014-12-24
CA2915811C (en) 2021-08-31
AU2014283319A1 (en) 2016-02-11
RU2016101152A (ru) 2017-07-24
ES3053333T3 (en) 2026-01-21
PT3010543T (pt) 2025-11-28
MX366353B (es) 2019-07-05
CN105658238B (zh) 2019-07-12
BR112015031835B1 (pt) 2022-12-13
SG11201510451RA (en) 2016-01-28

Similar Documents

Publication Publication Date Title
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
ME02910B (me) Spojevi tetrahidropirolotiazina
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
PH12021551589A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
IN2014DN09434A (es)
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
PH12016502353A1 (en) Pharmaceutical composition
PH12016502352A1 (en) Pharmaceutical composition
EA201692298A1 (ru) Производные карбоксамидов
UA117154C2 (uk) Антагоністи s1p3
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2015018040A (es) Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX381932B (es) Composicion intranasal que comprende betahistina.
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MY173812A (en) 2-pyridone compound
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
FG Grant or registration